Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 

Home Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 

Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 

Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 

/ Publications

Share the Post

About the Author

Related Posts

ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Mohammad Hirmand, MD
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts
nab-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program
Read More
Neil Desai, PhD
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Comments

Comments are closed.